Cell Biology Quiz: Antibiotics Mechanisms
20 questions · exam conditions
0:00
Antibiotics MechanismsQuestion 1 of 20

Tetracycline blocks bacterial protein synthesis. Why are human ribosomes spared?

Human ribosomes are mainly 70S
Bacterial ribosomes are 80S
Bacteria lack all ribosomes
Human ribosomes are mainly 80S
← Back to quizzes

Cell Biology Quiz

Cell Biology Quiz: Antibiotics Mechanisms

Practice Antibiotics Mechanisms in Cell Biology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Antibiotics Mechanisms, giving you a quick way to practice the rules, question types, and explanations that matter most for Cell Biology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Tetracycline blocks bacterial protein synthesis. Why are human ribosomes spared?

  1. Human ribosomes are mainly 70S
  2. Bacterial ribosomes are 80S
  3. Bacteria lack all ribosomes
  4. Human ribosomes are mainly 80S (correct answer)
Explanation: Tetracycline targets the 70S ribosome, which bacteria use for protein synthesis. Human cells have mainly 80S ribosomes, which do not bind tetracycline the same way, so human protein synthesis is spared. The tempting wrong choice is saying bacterial ribosomes are 80S, but bacteria actually have 70S ribosomes, while 80S ribosomes are eukaryotic.

Question 2

Which feature explains penicillin's selective toxicity?

  1. Human cells lack peptidoglycan (correct answer)
  2. Eukaryotic ribosomes are 80S
  3. Human cells lack DNA gyrase
  4. Human cells synthesize folate
Explanation: Penicillin blocks cross-linking of peptidoglycan, a polymer unique to bacterial cell walls. Because human cells have no peptidoglycan, the drug can kill bacteria while leaving your cells intact. The tempting error is DNA gyrase: that enzyme is a target for quinolone antibiotics, not penicillin.

Question 3

What makes fluoroquinolones selective against bacteria?

  1. Block human topoisomerase II
  2. Inhibit bacterial DNA gyrase (correct answer)
  3. Bind bacterial 50S subunit
  4. Block bacterial folate uptake
Explanation: Fluoroquinolones target bacterial DNA gyrase, an enzyme bacteria need for DNA replication, so they disrupt bacterial DNA while leaving human cells unharmed. The tempting distractor is blocking human topoisomerase II, but that would cause host toxicity, not selectivity; fluoroquinolones do not inhibit the human enzyme.

Question 4

Why do sulfonamides not harm human cells?

  1. Bacteria lack folate synthesis
  2. Humans make their own folate
  3. Humans lack folate synthesis (correct answer)
  4. Human ribosomes are 80S type
Explanation: Sulfonamides block the bacterial enzyme that makes folate, but human cells don't make folate at all, so there is no target for the drug to attack. You get folate from your diet instead. The tempting wrong answer is that humans make their own folate, but that would make you vulnerable, not protected.

Question 5

What is the basis of rifamycin's selective toxicity?

  1. Bind only human RNA polymerase
  2. Block bacterial DNA synthesis
  3. Block bacterial RNA polymerase (correct answer)
  4. Disrupt bacterial ribosomes
Explanation: Rifamycin selectively inhibits the bacterial enzyme RNA polymerase, blocking transcription of bacterial genes while leaving human RNA polymerase largely unaffected. That is the basis of its selective toxicity. A tempting wrong answer is that it blocks bacterial DNA synthesis, but rifamycin targets RNA synthesis, not DNA replication or ribosome function.

Question 6

A researcher is developing a new antibiotic and wants to ensure it will be selective for bacterial cells over human cells. The antibiotic functions by inhibiting the formation of peptide cross-links in cell wall synthesis. Which characteristic of the target structure makes this antibiotic selective?

  1. The target structure contains chitin instead of cellulose in human cells
  2. The target structure is absent in human cells but essential in bacterial cells (correct answer)
  3. The target structure uses different amino acids in human cells compared to bacterial cells
  4. The target structure is located in the cytoplasm of human cells but extracellular in bacteria
  5. The target structure is synthesized by ribosomes in bacteria but not in human cells
Explanation: When you encounter questions about antibiotic selectivity, focus on the fundamental structural differences between prokaryotic and eukaryotic cells. The key principle is that effective antibiotics target structures or processes that exist in bacteria but not in human cells, minimizing harm to the host. The antibiotic described inhibits peptide cross-link formation in cell wall synthesis. This targets peptidoglycan, a unique structural component of bacterial cell walls made of sugar chains connected by peptide bridges. Human cells completely lack cell walls and peptidoglycan—they're surrounded only by flexible plasma membranes. Since the target structure is essential for bacterial survival but entirely absent in human cells, the antibiotic achieves perfect selectivity. Looking at the wrong answers: (A) incorrectly suggests human cells have cell walls made of chitin, but humans have no cell walls at all—chitin is found in fungal cell walls and arthropod exoskeletons. (C) implies both cell types have the target structure but with different amino acids, which is false since humans lack peptidoglycan entirely. (D) misplaces the location of cell walls—bacterial cell walls are external structural barriers, not internal cytoplasmic components, and again, humans have no equivalent structure anywhere. Study tip: Remember the major structural differences between prokaryotes and eukaryotes. Bacteria have unique features like peptidoglycan cell walls, different ribosomes, and distinct metabolic pathways—these differences are exactly what antimicrobial drugs exploit. Always ask: "Does this structure/process exist in human cells?" when evaluating antibiotic selectivity.

Question 7

Streptomycin is an antibiotic that binds to the 30S ribosomal subunit and causes misreading of mRNA, leading to the production of defective proteins. Why does streptomycin preferentially affect bacterial cells rather than human cells?

  1. Human cells use tRNA molecules that are resistant to streptomycin interference
  2. Bacterial cells have a higher rate of protein synthesis than human cells
  3. Human ribosomes contain 40S and 60S subunits instead of 30S and 50S subunits (correct answer)
  4. Bacterial mRNA lacks the protective 5' cap structure found in human mRNA
  5. Human cells can repair misfolded proteins more efficiently than bacterial cells
Explanation: When you encounter questions about antibiotics and their selectivity, focus on the fundamental structural differences between prokaryotic and eukaryotic cells. Streptomycin's effectiveness as an antibiotic depends on targeting bacterial ribosomes while leaving human ribosomes unaffected. The key insight is that bacterial and human ribosomes have different compositions. Bacterial ribosomes are 70S ribosomes composed of 30S and 50S subunits, while human (eukaryotic) ribosomes are 80S ribosomes made of 40S and 60S subunits. Since streptomycin specifically binds to the 30S subunit, it can only affect bacterial ribosomes—human ribosomes simply don't have this target structure. This makes option C correct. Option A is incorrect because tRNA molecules aren't the primary target of streptomycin, and bacterial tRNA isn't inherently more susceptible than human tRNA. Option B misses the point entirely—while bacteria may synthesize proteins rapidly, this doesn't explain streptomycin's selectivity. The antibiotic works by targeting ribosome structure, not synthesis rate. Option D focuses on mRNA processing differences, but streptomycin's mechanism involves ribosome binding, not mRNA cap recognition. Remember this pattern: effective antibiotics exploit structural differences between bacterial and human cells. When you see questions about antibiotic selectivity, immediately think about what cellular component is being targeted and whether that structure differs between prokaryotes and eukaryotes. Ribosome composition is a classic example of such a difference.

Question 8

Ciprofloxacin is an antibiotic that inhibits DNA gyrase, an enzyme that relieves supercoiling tension during DNA replication. A patient asks why this drug doesn't interfere with human DNA replication. Which explanation is most accurate?

  1. Human DNA doesn't form supercoils during replication like bacterial DNA does
  2. Human cells use topoisomerase II which has a different structure than bacterial DNA gyrase (correct answer)
  3. Human DNA replication occurs in the nucleus where ciprofloxacin cannot penetrate
  4. Human cells replicate DNA more slowly so supercoiling tension doesn't build up
  5. Human DNA has a different base composition that doesn't require gyrase activity
Explanation: When you encounter questions about antibiotic selectivity, focus on the key principle: effective antibiotics target bacterial structures or enzymes that differ from their human counterparts, allowing them to kill bacteria while minimizing harm to human cells. Ciprofloxacin works because human cells use topoisomerase II to relieve DNA supercoiling, while bacteria use DNA gyrase. Although both enzymes perform similar functions, they have fundamentally different protein structures and active sites. This structural difference allows ciprofloxacin to selectively bind to and inhibit bacterial DNA gyrase without significantly affecting human topoisomerase II. The drug essentially acts like a key that fits the bacterial enzyme's lock but not the human enzyme's lock. Looking at the wrong answers: (A) is incorrect because human DNA absolutely does form supercoils during replication - this happens in any double-stranded DNA being unwound by helicases. (C) is wrong because ciprofloxacin can penetrate cell membranes and enter the nucleus; drug penetration isn't the selectivity mechanism here. (D) misses the mark because supercoiling tension builds up regardless of replication speed - it's a physical consequence of unwinding the double helix. Remember this pattern for antibiotic questions: selective toxicity usually stems from structural differences between bacterial and human proteins that perform similar functions. When you see questions about why antibiotics don't harm human cells, look for answers that highlight these molecular differences rather than claims about fundamental biological processes being absent in humans.

Question 9

Penicillin works by inhibiting transpeptidase enzymes that form cross-links in bacterial cell wall peptidoglycan. A student observes that penicillin is most effective against rapidly growing bacteria. Which factor best explains this observation?

  1. Rapidly growing bacteria have thinner cell walls that are easier to disrupt
  2. Fast-growing bacteria produce more transpeptidase enzymes for penicillin to target
  3. Cell wall synthesis is most active during rapid growth, making disruption more lethal (correct answer)
  4. Rapidly dividing bacteria cannot repair penicillin-induced damage as efficiently
  5. Fast growth increases bacterial membrane permeability to penicillin
Explanation: When you encounter questions about antibiotic mechanisms, focus on connecting the drug's specific action to when that cellular process is most critical for bacterial survival. Penicillin's effectiveness against rapidly growing bacteria stems from the timing of cell wall synthesis. During rapid bacterial growth and division, cells must continuously synthesize new peptidoglycan to expand their cell walls and form the septum that separates daughter cells. This makes cell wall synthesis absolutely essential for survival during active growth phases. When penicillin blocks transpeptidase enzymes during this critical period, it prevents proper cross-linking of peptidoglycan strands, leading to structural weakness and cell lysis. The more actively a bacterium is building its cell wall, the more devastating penicillin's interference becomes. Looking at the wrong answers: (A) incorrectly assumes rapidly growing bacteria have thinner walls - growth rate doesn't determine wall thickness. (B) suggests more transpeptidase enzymes create more targets, but penicillin's effectiveness isn't about enzyme quantity - it's about disrupting an essential process at a critical time. (D) proposes that dividing bacteria can't repair damage efficiently, but the real issue is that penicillin prevents proper wall construction during the most vulnerable phase, not repair capacity. Remember this pattern: antibiotics are typically most effective when they disrupt processes that are essential and actively occurring. Always consider the cellular context - when is the targeted process most critical for bacterial survival?

Question 10

Chloramphenicol inhibits the peptidyl transferase activity of bacterial ribosomes. However, this antibiotic can cause serious side effects in humans, including bone marrow suppression. What cellular characteristic explains why humans can experience these side effects?

  1. Human bone marrow cells have especially high concentrations of 70S ribosomes
  2. Chloramphenicol can also inhibit protein synthesis in human mitochondrial ribosomes (correct answer)
  3. Human bone marrow produces bacterial-like ribosomes during blood cell formation
  4. The drug accumulates in bone marrow and interferes with DNA replication
  5. Human 80S ribosomes become more sensitive to chloramphenicol during rapid cell division
Explanation: When you encounter questions about antibiotics affecting humans despite targeting bacterial processes, think about the evolutionary connections between bacterial and eukaryotic cellular components. Chloramphenicol specifically targets the peptidyl transferase center of 70S ribosomes found in bacteria. However, humans experience serious side effects because our mitochondria contain ribosomes that are remarkably similar to bacterial ribosomes. Mitochondrial ribosomes are also 70S ribosomes with similar peptidyl transferase activity, making them vulnerable to chloramphenicol inhibition. When the drug blocks protein synthesis in mitochondria, it severely impacts cellular energy production, particularly affecting rapidly dividing cells like those in bone marrow. Let's examine why the other options are incorrect. Option A suggests bone marrow cells have high concentrations of 70S ribosomes, but human cells contain 80S ribosomes in their cytoplasm, not 70S. Option C incorrectly claims that bone marrow produces bacterial-like ribosomes during blood cell formation—human cells always produce 80S ribosomes for cytoplasmic protein synthesis. Option D misidentifies the mechanism entirely, as chloramphenicol's primary effect is on protein synthesis, not DNA replication. The correct answer is B because mitochondrial ribosomes share structural similarities with bacterial ribosomes due to the endosymbiotic origin of mitochondria. Remember this key principle: when studying antibiotics, always consider that mitochondria retain many bacterial characteristics. This explains why several antibiotics that target bacteria can also cause mitochondrial toxicity in humans, particularly affecting energy-demanding tissues.

Question 11

Vancomycin prevents bacterial cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors. Some bacteria develop resistance by changing this terminus to D-Ala-D-Lac. Why doesn't this resistance mechanism significantly harm the bacteria?

  1. The D-Ala-D-Lac terminus forms stronger peptide cross-links than D-Ala-D-Ala
  2. Lactate is more readily available in bacterial cells than alanine
  3. The modified terminus can still be processed by transpeptidase enzymes for cross-linking (correct answer)
  4. D-Lac terminals are naturally found in some bacterial species
  5. The change only affects the outer layer of peptidoglycan, not the entire cell wall
Explanation: When you encounter questions about antibiotic resistance mechanisms, focus on whether the bacterial modification preserves essential cellular functions while evading the drug's target. Vancomycin works by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, preventing the transpeptidase enzymes from cross-linking the cell wall. However, when bacteria modify this terminus to D-Ala-D-Lac, the transpeptidase enzymes can still recognize and process these modified precursors for cross-linking. The key insight is that transpeptidases have sufficient flexibility in their active sites to accommodate the lactate substitution while maintaining their essential cross-linking function. This allows bacteria to build functional cell walls even with the modified terminus. Looking at the wrong answers: (A) is incorrect because D-Ala-D-Lac doesn't form stronger cross-links—the cross-link strength depends on the transpeptidase reaction, not the original terminus. (B) misses the point entirely, as lactate availability isn't the critical factor; it's whether the modified structure maintains function. (D) is misleading because while some bacteria may naturally have variations, this doesn't explain why the modification doesn't harm the resistant bacteria. The resistance works because it's a "stealth" modification—the bacteria change just enough to evade vancomycin binding while preserving the essential biochemical compatibility with their own enzymes. Study tip: For antibiotic resistance questions, always ask: "Does this change preserve the bacteria's essential function while blocking the antibiotic's mechanism?" Successful resistance mechanisms must do both.

Question 12

Tetracycline binds to the A-site of bacterial ribosomes and prevents tRNA from delivering amino acids during translation. A researcher notices that tetracycline resistance often involves efflux pumps that remove the drug from bacterial cells. What does this suggest about tetracycline's mechanism compared to other protein synthesis inhibitors?

  1. Tetracycline binding to ribosomes is reversible, unlike other protein synthesis inhibitors
  2. Tetracycline requires higher intracellular concentrations to be effective than irreversible inhibitors
  3. Efflux pumps are more effective against drugs that target the ribosomal A-site
  4. Tetracycline must compete with tRNA for binding, requiring sustained drug levels (correct answer)
  5. Other protein synthesis inhibitors are too large to be removed by efflux pumps
Explanation: When analyzing antibiotic mechanisms, you need to consider whether the drug's binding is competitive or non-competitive, and how this affects the concentration requirements for effectiveness. Tetracycline works by binding to the ribosomal A-site where tRNA normally delivers amino acids. This creates a competitive inhibition scenario - tetracycline and tRNA are literally competing for the same binding site. For tetracycline to be effective, it must maintain high enough concentrations to outcompete tRNA binding consistently. If drug levels drop, tRNA can successfully bind and protein synthesis resumes. This explains why efflux pumps (which continuously remove tetracycline from cells) are such an effective resistance mechanism - they prevent the sustained high concentrations needed for competitive inhibition. Looking at the incorrect options: (A) is wrong because many protein synthesis inhibitors have reversible binding, not just tetracycline. (B) misses the key point about competition - the issue isn't simply higher concentrations versus irreversible inhibitors, but rather the competitive nature requiring sustained levels. (C) incorrectly suggests that efflux pumps are specifically more effective against A-site targeting drugs, when efflux pumps work by removing any drug regardless of its ribosomal target. The correct answer is (D) because it identifies the competitive relationship between tetracycline and tRNA, which necessitates sustained drug concentrations to maintain inhibition. Remember: competitive inhibitors require sustained concentrations because they must continuously outcompete the natural substrate. This makes them particularly vulnerable to resistance mechanisms that reduce intracellular drug concentrations, like efflux pumps.

Question 13

Polymyxin B is an antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides. This drug shows significant toxicity to human kidney cells. Which feature of human kidney cells most likely explains this toxicity?

  1. Kidney cells contain lipopolysaccharides similar to those found in bacteria
  2. Kidney cells have unusually thin cell membranes that are easily disrupted
  3. The drug concentrates in kidney tissue during excretion and disrupts membrane integrity (correct answer)
  4. Kidney cells produce enzymes that convert polymyxin B into a more toxic form
  5. The high metabolic activity of kidney cells makes them more sensitive to membrane disruption
Explanation: When you encounter questions about drug toxicity, think about how the drug's mechanism of action might affect human tissues, especially considering the drug's pathway through the body. Polymyxin B targets bacterial lipopolysaccharides to disrupt cell membranes, but its toxicity to kidney cells stems from pharmacokinetics rather than shared cellular components. The kidney is the primary route of excretion for many antibiotics, including polymyxin B. As the drug is filtered and concentrated in kidney tubules during urine formation, it reaches much higher local concentrations than in other tissues. At these elevated concentrations, polymyxin B becomes non-specific and can disrupt the phospholipid membranes of human kidney cells, leading to nephrotoxicity. Option A is incorrect because human cells don't contain lipopolysaccharides—these are unique components of bacterial outer membranes, particularly in gram-negative bacteria. Option B misrepresents kidney cell structure; these cells don't have unusually thin membranes compared to other human cells. The membrane thickness isn't the issue here. Option D suggests metabolic activation, but polymyxin B doesn't require enzymatic conversion to become toxic—it's directly membrane-active at high concentrations. The correct answer is C because it correctly identifies that drug concentration during renal excretion is the key factor explaining kidney toxicity. Remember this pattern: when antibiotics cause organ-specific toxicity, consider the drug's elimination pathway. Drugs excreted by the kidneys often cause nephrotoxicity due to local concentration effects, while drugs metabolized by the liver may cause hepatotoxicity.

Question 14

Rifampin inhibits bacterial RNA polymerase by binding to the β-subunit and blocking RNA exit from the enzyme. This antibiotic is highly selective for bacteria, but resistance can develop through mutations in the rpoB gene. Why do these resistance mutations typically reduce bacterial fitness?

  1. The mutations make RNA polymerase less stable at normal body temperature
  2. Modified RNA polymerase produces RNA with more transcription errors
  3. The rpoB mutations also affect other essential genes located nearby
  4. Resistance mutations often alter RNA polymerase function even when rifampin is absent (correct answer)
  5. Mutant bacteria become more susceptible to other antibiotics that target transcription
Explanation: When you encounter questions about antibiotic resistance, think about the trade-offs bacteria face between survival and optimal function. Resistance mutations don't exist in a vacuum—they often come with costs. Rifampin resistance occurs through mutations in the rpoB gene, which encodes the β-subunit of bacterial RNA polymerase. While these mutations prevent rifampin from binding effectively, they typically alter the enzyme's structure in ways that also affect its normal function. RNA polymerase is a highly optimized molecular machine, and any structural changes that block antibiotic binding often simultaneously reduce the enzyme's efficiency, processivity, or regulation during normal transcription. This creates a fitness cost—the bacteria can survive rifampin treatment, but they don't function as well as wild-type bacteria in antibiotic-free environments. Option A is incorrect because resistance mutations don't typically affect thermal stability—bacteria maintain RNA polymerase function at physiological temperatures. Option B misses the mark; while transcription efficiency may decrease, the primary issue isn't increased error rates but rather reduced overall performance. Option C incorrectly suggests the problem is with nearby genes, when the fitness cost stems directly from the altered RNA polymerase itself, not neighboring genetic elements. Remember this key principle: resistance mutations often involve a fitness trade-off. The same structural changes that confer resistance frequently impair normal protein function, which is why resistant bacteria may be outcompeted by sensitive strains when antibiotics aren't present. This concept applies broadly across different resistance mechanisms.

Question 15

Lincomycin works by binding to the 50S ribosomal subunit and preventing the formation of peptide bonds. A microbiologist observes that this antibiotic is bacteriostatic (stops growth) rather than bactericidal (kills bacteria) under most conditions. What aspect of its mechanism explains this observation?

  1. The antibiotic only blocks new protein synthesis without damaging existing proteins
  2. Lincomycin binding to ribosomes is easily reversible when the drug is removed
  3. Bacteria can survive temporarily using pre-existing proteins while ribosomes are blocked (correct answer)
  4. The drug only affects ribosomes that are actively translating at the time of exposure
  5. Lincomycin concentrations decrease rapidly due to bacterial enzyme degradation
Explanation: When you encounter questions about antibiotic mechanisms, focus on the difference between bacteriostatic (growth inhibition) and bactericidal (cell death) effects. This distinction often relates to whether the drug disrupts essential ongoing processes or destroys critical cellular structures. Lincomycin blocks protein synthesis by preventing peptide bond formation at the 50S ribosomal subunit. However, bacteria don't immediately die because they can survive temporarily using the proteins they already have. Essential enzymes, structural proteins, and other cellular components that were synthesized before antibiotic exposure remain functional and can sustain basic cellular processes for a period of time. This explains why lincomycin is bacteriostatic rather than bactericidal - it prevents new growth and reproduction by blocking new protein production, but doesn't directly kill the bacteria. Answer A is incorrect because while lincomycin doesn't damage existing proteins, this alone doesn't explain the bacteriostatic nature - the key is that existing proteins can sustain the cell temporarily. Answer B misrepresents the mechanism; the bacteriostatic effect isn't primarily about reversibility, but about cellular survival using pre-existing proteins. Answer D is wrong because lincomycin affects all 50S ribosomal subunits it encounters, not just those actively translating. Remember that bacteriostatic antibiotics typically target processes essential for growth and reproduction (like protein or DNA synthesis) while leaving existing cellular machinery intact, whereas bactericidal antibiotics often disrupt cell walls, membranes, or other structures critical for immediate survival.

Question 16

Novobiocin inhibits bacterial DNA gyrase by binding to the GyrB subunit and preventing ATP hydrolysis. This differs from ciprofloxacin, which binds to the GyrA subunit. A researcher finds that some bacteria resistant to ciprofloxacin remain sensitive to novobiocin. What does this suggest about the resistance mechanisms?

  1. Ciprofloxacin resistance involves efflux pumps that don't recognize novobiocin
  2. The bacteria have mutations in gyrA but not in gyrB genes (correct answer)
  3. Novobiocin has a different mechanism that doesn't involve DNA gyrase
  4. Ciprofloxacin-resistant bacteria overproduce the GyrB subunit
  5. The two drugs bind to different cellular locations within the bacteria
Explanation: When you encounter questions about antibiotic resistance mechanisms, focus on the specific molecular targets and how resistance can arise through different pathways. DNA gyrase is essential for bacterial DNA replication and consists of two subunits: GyrA and GyrB. Ciprofloxacin (a quinolone) binds to GyrA, while novobiocin targets GyrB and blocks ATP hydrolysis. The key insight here is that if bacteria are resistant to ciprofloxacin but still sensitive to novobiocin, the resistance mechanism must be specific to ciprofloxacin's target. This pattern strongly suggests mutations in the gyrA gene that alter the GyrA subunit, making it unable to bind ciprofloxacin effectively. Since the bacteria remain sensitive to novobiocin, their GyrB subunit is still functional and can be inhibited normally. Answer B correctly identifies this mechanism. Let's examine why the other options fail: A) While efflux pumps can cause antibiotic resistance, this wouldn't explain the selective pattern observed—if efflux pumps were removing ciprofloxacin, you'd expect some cross-resistance patterns, not the clean separation described. C) This is factually incorrect—novobiocin definitely targets DNA gyrase, specifically the GyrB subunit. D) Overproducing GyrB wouldn't cause ciprofloxacin resistance since ciprofloxacin targets GyrA, not GyrB. Remember: when analyzing antibiotic resistance patterns, always consider which specific molecular target is affected. Resistance to one drug but sensitivity to another drug targeting the same protein complex usually indicates mutations in the specific binding site of the first drug's target.

Question 17

Bacitracin prevents bacterial cell wall synthesis by binding to undecaprenyl phosphate, a lipid carrier that transports peptidoglycan precursors across the cell membrane. This antibiotic is typically used only topically (on skin surfaces) rather than systemically. What property of bacitracin most likely explains this limitation?

  1. Bacitracin is rapidly inactivated by human digestive enzymes
  2. The drug cannot cross human cell membranes to reach internal infection sites
  3. Bacitracin causes significant toxicity to human cells when used systemically (correct answer)
  4. The antibiotic is only effective against bacteria that grow in aerobic conditions
  5. Systemic use leads to rapid development of bacterial resistance to bacitracin
Explanation: When you encounter questions about why certain antibiotics have limited clinical use, focus on the therapeutic window—the difference between an effective dose and a toxic dose. Antibiotics must selectively target bacterial cells while minimizing harm to human cells. Bacitracin exemplifies this challenge perfectly. While it effectively disrupts bacterial cell wall synthesis by interfering with peptidoglycan transport, it also causes significant nephrotoxicity (kidney damage) and other serious side effects when administered systemically. The concentration needed to treat internal infections would cause unacceptable harm to human tissues, particularly the kidneys. This is why bacitracin is restricted to topical use, where high local concentrations can kill bacteria on skin surfaces without reaching toxic systemic levels. Answer C correctly identifies this toxicity limitation. Option A is incorrect because digestive enzyme inactivation wouldn't prevent intravenous or intramuscular administration—many antibiotics bypass the digestive system entirely. Option B misrepresents the issue; bacitracin can cross human cell membranes, but the problem is what happens when it does (toxicity), not an inability to reach infection sites. Option D is wrong because bacitracin's mechanism (blocking cell wall synthesis) works against both aerobic and anaerobic bacteria—oxygen availability doesn't affect peptidoglycan synthesis. Remember that when you see questions about antibiotic limitations, always consider the therapeutic window. Many potentially effective drugs remain topical or are discontinued entirely because they can't achieve safe systemic concentrations. Selectivity for bacterial over human cells is crucial for any systemically administered antibiotic.

Question 18

Spectinomycin binds to the 30S ribosomal subunit and inhibits bacterial protein synthesis by blocking translocation of the ribosome along mRNA. Unlike streptomycin, spectinomycin does not cause significant misreading of the genetic code. How does this difference in mechanism affect the clinical outcome?

  1. Spectinomycin is more likely to select for resistant bacteria than streptomycin
  2. Spectinomycin is bacteriostatic while streptomycin tends to be bactericidal (correct answer)
  3. Spectinomycin requires higher doses to achieve the same therapeutic effect
  4. Spectinomycin is less likely to cause damage to human inner ear cells
  5. Spectinomycin can be used safely in patients with kidney disease
Explanation: When you encounter questions about antibiotic mechanisms, focus on how the specific mode of action translates to clinical effects. The key distinction here is between blocking protein synthesis completely versus causing errors in protein production. Spectinomycin blocks ribosomal translocation, which stops protein synthesis entirely but allows existing proteins to continue functioning temporarily. This makes it bacteriostatic—it halts bacterial growth and reproduction but doesn't immediately kill the bacteria. Streptomycin, however, causes misreading of mRNA, leading to production of defective, often toxic proteins that actively damage bacterial cell components. This direct cellular damage makes streptomycin bactericidal. Looking at the wrong answers: (A) is incorrect because resistance development depends more on antibiotic pressure and usage patterns than the specific killing mechanism. (C) is wrong—dose requirements relate to drug pharmacokinetics and target affinity, not whether the drug is bacteriostatic or bactericidal. (D) misses the point entirely; both drugs can potentially affect human ribosomes, but the question focuses on their different mechanisms against bacteria, not human toxicity profiles. The correct answer is (B) because the mechanism directly determines the clinical effect: complete blockade of protein synthesis (spectinomycin) typically results in growth inhibition rather than cell death, while error-inducing mechanisms (streptomycin) often prove lethal to bacteria. Remember this pattern: antibiotics that completely block essential processes tend to be bacteriostatic, while those that cause cellular damage or toxic product formation are more likely bactericidal.

Question 19

Fosfomycin inhibits bacterial cell wall synthesis by irreversibly binding to MurA, the enzyme that catalyzes the first step in peptidoglycan synthesis. A clinical study shows that fosfomycin resistance develops slowly compared to other cell wall synthesis inhibitors. What feature of fosfomycin's mechanism contributes to this slower resistance development?

  1. The drug targets the first enzymatic step, making bypass mutations less likely
  2. Irreversible binding means bacteria cannot develop efflux-based resistance
  3. MurA enzyme is essential and highly conserved, limiting viable resistance mutations (correct answer)
  4. Fosfomycin has multiple binding sites on the target enzyme
  5. The drug accumulates intracellularly and maintains effective levels longer
Explanation: When you encounter questions about antibiotic resistance development, focus on the relationship between a drug's target characteristics and the likelihood of viable resistance mutations emerging. Fosfomycin's slow resistance development stems from its target's essential nature and evolutionary conservation. MurA catalyzes the very first step in peptidoglycan synthesis, converting UDP-N-acetylglucosamine to UDP-N-acetylglucosamine-enolpyruvate. This enzyme is absolutely critical for bacterial survival and has remained highly conserved across bacterial species due to strong evolutionary pressure. When a protein is both essential and conserved, most mutations that alter its structure enough to prevent drug binding will also disrupt its vital cellular function, making those mutations lethal rather than advantageous. This severely limits the number of viable resistance mutations that can arise. Let's examine why the other options miss the mark. Choice A incorrectly assumes that targeting early pathway steps inherently prevents bypass mutations, but bacteria can develop resistance to first-step inhibitors through various mechanisms. Choice B misunderstands efflux resistance—irreversible binding doesn't prevent bacteria from developing pumps that remove the drug before it reaches its target. Choice D is factually incorrect; fosfomycin has a specific, single binding site on MurA. The key takeaway: when evaluating why resistance develops slowly for any antimicrobial, look for targets that are both essential for survival and highly conserved. These constraints dramatically reduce the evolutionary "space" available for viable resistance mutations, explaining fosfomycin's relatively durable effectiveness compared to drugs targeting less constrained proteins.

Question 20

A novel antibiotic targets bacterial DNA polymerase III, the main replicative enzyme in bacteria. During preclinical testing, researchers find that the drug also affects human cells, but only at concentrations 50 times higher than those needed to inhibit bacteria. What factor most likely accounts for this selectivity ratio?

  1. Human DNA polymerases have different cofactor requirements than bacterial enzymes
  2. The antibiotic has higher binding affinity for bacterial DNA polymerase III than human DNA polymerases (correct answer)
  3. Human cells replicate DNA less frequently than bacterial cells
  4. Bacterial DNA polymerase III has a different proofreading mechanism than human polymerases
  5. The drug is actively transported into bacterial cells but not human cells
Explanation: When you encounter questions about drug selectivity between bacterial and human cells, focus on the fundamental differences in molecular structure and binding interactions between prokaryotic and eukaryotic enzymes. The 50-fold selectivity ratio indicates that this antibiotic binds much more tightly to bacterial DNA polymerase III than to human DNA polymerases. This difference in binding affinity is the most direct explanation for why you need 50 times more drug to affect human cells. The antibiotic likely exploits structural differences in the enzyme's active site or binding pockets that evolved differently in bacteria versus humans, allowing for preferential binding to the bacterial target. Let's examine why the other options don't explain this selectivity pattern. Option A about different cofactor requirements doesn't account for the specific concentration difference observed—cofactor differences would more likely result in complete selectivity rather than a 50-fold ratio. Option C regarding replication frequency affects how often the target enzyme is active, but doesn't explain why higher drug concentrations are needed to inhibit human polymerases when they are active. Option D about proofreading mechanisms focuses on enzyme function after DNA synthesis, which wouldn't directly impact the drug's ability to bind and inhibit the polymerase itself. Remember that selective drug toxicity typically results from evolutionary differences in protein structure between species. When you see questions about antimicrobial selectivity, look for answers that address binding affinity or structural differences between the pathogen and host targets—this is the foundation of effective antimicrobial design.